#United States #New York #Turn Biotechnologies #Klotho Neurosciences #longevity therapies

Klotho Neurosciences Pursues Acquisition to Enhance Longevity Therapies

In a significant move for the future of longevity medicine, Klotho Neurosciences, Inc. (NASDAQ: KLTO) announced today that it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. This acquisition, which is poised to reshape Klotho's position in the burgeoning field of regenerative therapies, includes Turn's innovative ERA platform focused on cellular rejuvenation and its eTurna RNA delivery system.

This LOI is part of a larger strategy by Klotho to establish itself as a leader in developing therapeutics that extend healthspan. The proposed deal, which involves a mix of cash and equity, is contingent upon completing due diligence and finalizing a definitive agreement. Among the most noteworthy aspects of the acquisition is a collaboration with a leading South Korean pharmaceutical firm, with the partnership valued at up to $300 million. This sizable investment highlights the market's optimism regarding Turn’s technologies and their potential applications across various therapeutic areas.

Dr. Joseph Sinkule, the CEO of Klotho, commented on the acquisition: "This LOI marks a transformative step for Klotho. The Klotho gene, often referred to as the anti-aging gene, has been recognized for its potential to extend lifespan and combat neurodegenerative diseases. By integrating Turn's advanced ERA technology, which utilizes RNA molecules to reset cellular aging, we are advancing our goal of developing effective treatments against age-related conditions. Our mission has always been to tackle aging at its source by focusing on cellular health."

The ERA (Epigenetic Reprogramming of Age) platform, developed at Stanford University, employs a unique delivery system aimed at rejuvenating somatic cells and restoring tissue function. This technology opens the doors to regenerative therapies that could significantly improve treatment options in dermatology, immunology, osteoarthritis, and conditions such as amyotrophic lateral sclerosis (ALS).

Klotho's CEO emphasized the strategic importance of the partnership with Turn, stating that it exemplifies both scientific and commercial viability, placing Klotho in a prime position to spearhead therapeutic innovations targeting diseases linked to aging, including Alzheimer's, Parkinson's, and various muscle and skin disorders.

Once the acquisition is finalized, Klotho plans to rebrand itself to better reflect its expanded mission within the longevity sector. It will also look to integrate key personnel from Turn’s management and research and development teams following the deal's closure, thereby enriching its expertise and accelerating its growth trajectory.

The longevity medicine market is experiencing rapid expansion, primarily driven by the aging global population, which is projected to reach 2.1 billion by 2050. As healthcare expenditures soar, accounting for an expected 10% of global GDP and projected to surpass $47 trillion by 2030, Klotho is setting its sights on being at the forefront of this transformation by addressing the fundamental aspects of aging.

In summary, the proposed acquisition of Turn Biotechnologies' assets represents an ambitious step for Klotho Neurosciences, positioning the company to leverage pioneering research and technologies at a time when demand for innovative age-related therapies has never been greater. As the landscape of healthcare continues to evolve, Klotho is determined to play a key role in changing how we perceive and address the natural aging process.